The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index; 8 of the 43 sources its claims cite were checked for support.
Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies
Open accessAbstract
STUDY QUESTION: What is the degree of intrinsic insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) and the relative contribution of BMI to overall IR based on meta-analysis of gold standard insulin clamp studies? SUMMARY ANSWER: We report an inherent reduction (-27%) of insulin sensitivity (IS) in PCOS patients, which was independent of BMI. WHAT IS ALREADY KNOWN: PCOS is prevalent, complex and underpinned by IR but controversies surround the degree of intrinsic IR in PCOS, the effect of BMI and the impact of the different diagnostic criteria (NIH versus Rotterdam) in PCOS. STUDY DESIGN, SIZE, DURATION: A systematic review and meta-analysis of Medline and All EBM databases was undertaken of studies published up to 30 May 2015. Studies were included if premenopausal women diagnosed with PCOS were compared with a control group for IS, measured by the gold standard euglycaemic-hyperinsulinaemic clamp. The systematic review adheres to the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Meta-analyses were performed using mixed modelling and magnitude-based inferences expressed as mean effect ±99% CI. We inferred the effect was small, moderate or large relative to a smallest important change of -3.7% or 3.8% derived by standardisation. Effects were deemed unclear when the CI overlapped smallest important positive and negative values. Effects were qualified with probabilities reflecting uncertainty in the magnitude of the true value (likely, 75-95%; very likely, 95-99.5%; most likely, >99.5%). PARTICIPANTS/MATERIALS, SETTING, METHOD: A total of 4881 articles were returned from the search. Of these, 28 articles were included in the meta-analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Overall IS was lower in women with PCOS compared with controls (mean effect -27%, 99% CI ±6%; large, most likely lower). A higher BMI exacerbated the reduction in IS by -15% (±8%; moderate, most likely lower) in PCOS compared with control women. There was no clear difference in IS between women diagnosed by the original National Institutes of Health (NIH) criteria alone compared with those diagnosed by the Rotterdam criteria. Low levels of sex hormone-binding globulin (SHBG) were associated with reduced levels of IS (-10%, ±10%; small, very likely negative), which was not confounded by BMI. LIMITATIONS, REASONS FOR CAUTION: This systematic review and meta-analysis inherited the confounding problems of small sample sizes, missing data (e.g. some hormones, waist and hip girths) and the lack of Rotterdam criteria phenotype reporting, limiting the evidence synthesis and meta-analysis. WIDER IMPLICATIONS OF THE FINDINGS: BMI has a greater impact on IS in PCOS than in controls. SHBG appears a potentially valuable marker of IR in PCOS, whereas testosterone after adjustment for BMI demonstrated an unexpected interplay with IS which warrants further investigation. STUDY FUNDING/COMPETING INTERESTS: This work was supported by grants from the National Health & Medical Research Council (NHMRC), grant number 606553 (H.J.T., N.K.S.), as well as Monash University. H.J.T. is an NHMRC Research Fellow. N.K.S. is supported through the Australian Government's Collaborative Research Networks (CRN) programme. The funding bodies played no role in the design, methods, data management or analysis or in the decision to publish. All authors declare no conflict of interests. REGISTRATION NUMBER: N/A.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 43 cited sources checked · 4 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“recent genome-wide association studies in Caucasian (Day et al., 2015;Hayes et al., 2015) and Asian (Chen et al., 2011;Shi et al., 2012) PCOS populations report preservation of genes across both criteria.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
- Supportedcites Day et al., 2015 source
The Methods (Follow-up studies) report separate analyses using Rotterdam and NIH PCOS criteria. The Results (Genome-wide association signals for PCOS) state that all six significant signals had directionally concordant associations in clinically validated follow-up cases, with no significant heterogeneity by case definition. Day et al. studied women of White European ancestry; the sentence cites separate studies for the Asian populations. (LLM, conf=0.88)
- Supportedcites Hayes et al., 2015 source
The Discussion reports that this European-ancestry study used the NIH phenotype while the Chinese GWAS included additional Rotterdam phenotypes. It also reports nominal replication of seven of eleven previously identified Chinese PCOS SNPs and a shared 9q22.32 locus, supporting overlap in genetic findings across the criteria. The paper does not claim that every associated gene is shared. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites Chen et al., 2011 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The most consistently observed androgenic abnormality in PCOS is elevated 'free testosterone' or calculated free androgen index, which includes SHBG in the equation (Teede et al., 2011).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Partly supportedcites Teede et al., 2011 sourceExperimental — accuracy not yet measured
The Clinical practice points say calculated free testosterone is a commonly measured marker and that the free androgen index is calculated from testosterone and SHBG. The evidence-based recommendation lists both as first-line tests for biochemical hyperandrogenism in PCOS. Neither passage establishes that their elevation is the most consistently observed androgenic abnormality. (LLM, conf=0.86)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Differences in study or subject characteristics, including inherent problems in analysing and reporting data from the euglycaemic-hyperinsulinaemic clamp, recruitment strategies, ethnicity and lifestyle factors (Day et al., 2015) may account for some of the unexplained effects of PCOS on IR.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Partly supportedcites Day et al., 2015 sourceExperimental — accuracy not yet measured
The paper discusses heterogeneity among PCOS cases (opening section; no page available) and differences between self-reported and clinically validated recruitment (Discussion; no page available). It does not discuss problems analysing or reporting euglycaemic-hyperinsulinaemic clamp data, or propose ethnicity and lifestyle differences as explanations for unexplained effects of PCOS on insulin resistance. (LLM, conf=0.83)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a 10-unit higher BMI in women with PCOS was associated with a -28% (±14%; large, most likely) difference in IS.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Moderating effects of BMI on IS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total testosterone, when the confounding effects of BMI were controlled, had a moderate and very likely effect on IR.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no clear difference in IS between women diagnosed by the original National Institutes of Health (NIH) criteria alone compared with those diagnosed by the Rotterdam criteria.”
- Also stated in: § Moderating effects of diagnostic criteria as a surrogate for phenotype · plain
“The effect of PCOS on IS was large for both diagnostic criteria groupings and there was no difference between them (Table IV).”
- Also stated in: § Discussion · plain
“PCOS diagnostic criteria had a trivial effect on IR.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Moderating effects of diagnostic criteria as a surrogate for phenotype · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A higher BMI exacerbated the reduction in IS by -15% (±8%; moderate, most likely lower) in PCOS compared with control women.”
- Also stated in: § Discussion · plain
“BMI independently exacerbated IR by 15% in PCOS, and had a greater impact than in controls.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall IS was lower in women with PCOS compared with controls (mean effect -27%, 99% CI ±6%; large, most likely lower).”
- Also stated in: § Overall relationship between IS and PCOS · plain
“In the first simple meta-analysis model, IS was lower in women with PCOS compared with controls (a large difference; Table IV).”
- Also stated in: § Discussion · plain
“we report that women with PCOS have 27% worse IS as a measure of IR from the gold standard euglycaemic-hyperinsulinaemic clamp, than controls, independent of BMI, age or diagnostic criteria.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Overall relationship between IS and PCOS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in control women the difference in IS for women 10 years older was 4% (±33%; unclear, small effect).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Moderating effects of age on IS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Higher LH concentrations in women with PCOS tended (unclear effect) to be associated with lower IS”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > IS, SHBG and hormone concentrations
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
- Probably not a substantial claim. 18
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This approach identified three clear outliers (Micic et al., 2007;Yang et al., 2013;Wu et al., 2014).”
- Also stated in: § Publication bias and outliers · plain
“The other two studies were excluded from the meta-analysis (Supplementary Fig. S1).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Publication bias and outliers
What the sources say
- Not checked — no full text of the sourcecites Micic et al., 2007 source
- Supportedcites Yang et al., 2013 source
The citation identifies Yang et al. (2013) as one of the studies the citing authors classified as outliers. Our copy’s Results section reports Yang et al.’s own ZAG study; the outlier classification, correction, and exclusions are the citing authors’ meta-analytic decisions, not findings attributed to Yang et al. (LLM, conf=0.86)
- Not matchedcites Wu et al., 2014
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
- Also stated in: § Publication bias and outliers · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“IR (defined as reduced insulin sensitivity [IS] compared with control women) and hyperandrogenism play key roles in the aetiology (Teede et al., 2007(Teede et al., , 2010)).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
- Not checked — no full text of the sourcecites Teede et al., 2007 source
- Supportedcites Teede et al., 2010 source
The Introduction section, “Aetiology: insulin resistance and hyperandrogenism,” explicitly identifies hyperandrogenism as an established contributor to PCOS aetiology and insulin resistance as a pathophysiological contributor. It notes that insulin resistance occurs in around 50%–80% of women with PCOS, so the claim does not imply that it is present in every case. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarities in IR may be related to genetic variations that are preserved across these criteria (Chen et al., 2011;Day et al., 2015;Hayes et al., 2015), suggesting a homogenous disease origin linked to insulin-related genes (Shi et al., 2012).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Not checked — no full text of the sourcecites Chen et al., 2011 source
- Partly supportedcites Day et al., 2015 sourceExperimental — accuracy not yet measured
The Methods (Follow-up studies; page unavailable) compare PCOS cases defined by Rotterdam and NIH criteria, and the Results (Genome-wide association signals for PCOS; page unavailable) report directionally concordant genetic associations with no significant heterogeneity by case definition. The Results (Mendelian randomization analyses; page unavailable) also link genetically predicted insulin resistance to PCOS risk, but do not show that similarities in insulin resistance across the two diagnostic groups arise from the same variants. The sentence cites Shi et al., not Day et al., for the separate suggestion of a homogeneous disease origin. (LLM, conf=0.86)
- Partly supportedcites Hayes et al., 2015 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a PCOS susceptibility locus found in both the NIH-phenotype cohort and a Chinese cohort that included additional Rotterdam phenotypes. It does not link that shared locus to similarities in insulin resistance (IR); it says the NIH phenotype has the highest IR risk and emphasizes gonadotropin-related genes. The sentence cites Shi et al., not Hayes et al., for the separate suggestion about insulin-related genes. (LLM, conf=0.84)
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with their respective controls, lean and overweight women with PCOS showed lower IS with large and very large magnitudes respectively (Table IV, Fig. 3).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Moderating effects of BMI on IS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Low levels of sex hormonebinding globulin (SHBG) were associated with reduced levels of IS (-10%, ±10%; small, very likely negative), which was not confounded by BMI.”
- Also stated in: § IS, SHBG and hormone concentrations · plain
“The mean lower concentration of SHBG in PCOS compared with controls was associated with a small lower IS, which was not confounded by BMI.”
- Also stated in: § Discussion · boosted
“SHBG had a strong negative association with IR, which was not confounded by BMI.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § IS, SHBG and hormone concentrations · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with their respective controls, younger and older women with PCOS showed lower or much lower IS, respectively (large and very large magnitudes).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Moderating effects of age on IS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FSH concentrations did not differ between PCOS and controls.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increasing age adversely impacted IR, yet the impact was trivial when adjusted for BMI and diagnostic criteria.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Testosterone means were higher in PCOS and were associated with worse IS but the relationship indicates women with less testosterone are more insulin resistant at the same BMI.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > IS, SHBG and hormone concentrations
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Older women diagnosed with PCOS had a lower IS compared with younger women with PCOS (a large magnitude), but this effect became small and unclear when BMI and diagnostic criteria were included in the model (Table IV).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Moderating effects of age on IS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“while FSH had a trivial relationship with only minor differences in FSH concentration between PCOS and control women.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > IS, SHBG and hormone concentrations
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The unexplained residual differences between studies, represented by the random effect, were large (~21%) but fell to moderate, when all predictors were included in the model (Hopkins et al., 2009).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Not checked — no full text of the sourcecites Hopkins et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“We also confirm that SHBG is not only lower, but also less variable in PCOS, compared with controls (Jayagopal et al., 2003), with larger studies now needed to derive specific SHBG cut-off ranges to predict IR.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Not checked — no full text of the sourcecites Jayagopal et al., 2003 source
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We report that PCOS has an intrinsic IR with a 27% lower IS, independent of BMI, with results that are statistically qualitatively 'large' and 'most likely', as defined here.”
- Also stated in: § Discussion · plain
“Overall mean -27, ±6 Large****”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Conclusion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Discussion · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, we address these gaps and advance the field by confirming in a robust systematic review and meta-analysis, that PCOS is underpinned by an intrinsic IR (~27% reduction in IS), independent of BMI and age, as well as across different diagnostic criteria and ethnic groups.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Consensus is yet to be achieved in lean women with PCOS as IR is not consistently demonstrated (Diamanti-Kandarakis and Dunaif, 2012).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
- Not checked — no full text of the sourcecites Diamanti-Kandarakis and Dunaif, 2012 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“two independent reviewers scanned the titles, abstracts and keywords of every record retrieved.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Study selection
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Risk of bias of the included studies was assessed by a reviewer using criteria developed a priori (Harris, 2010).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Data extraction and quality assessment
What the sources say
- Not matchedcites Harris, 2010
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Obesity is known to increase circulating androgen and insulin levels, may increase PCOS prevalence and exacerbates the clinical features of PCOS (Fig. 1; Diamanti-Kandarakis and Dunaif, 2012;Teede et al., 2013).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“IR and hyperinsulinaemia may directly stimulate production of androgens via ovarian tissue steroidogenesis, independently of changes in gonadotrophin concentration (Diamanti-Kandarakis and Dunaif, 2012).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
- Not checked — no full text of the sourcecites Diamanti-Kandarakis and Dunaif, 2012 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The systematic review adheres to the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.”
- Also stated in: § Materials and Methods · plain
“The methodology adheres to the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) Protocols.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Abstract
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § Materials and Methods · plain
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“This suggests a more homogeneous disease and highlights the need for further research into features such as IR in women with Rotterdam diagnosed PCOS (Barber et al., 2007;Panidis et al., 2012).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The strength of this meta-analysis is the extensive and comprehensive literature search and the focus on studies using gold standard methods to measure IR.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A meta-analysis cannot solve inherent confounding problems in included studies, which may exaggerate or underestimate effects.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Strength:plain· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This is in contrast to our current understanding of the interplay between androgens and IR (Diamanti-Kandarakis and Dunaif, 2012).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Not checked — no full text of the sourcecites Diamanti-Kandarakis and Dunaif, 2012 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The recent NIH consensus workshop on PCOS endorsed the Rotterdam criteria as the definitive diagnostic criteria (National Institutes of Health, 2012) and recommended that all studies include analyses by reproductive PCOS phenotype.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Not matchedcites National Institutes of Health, 2012
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“There was a lack of available robust trials and challenges of extracting reported data from the included studies as outlined.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“IR can be measured using numerous direct and indirect techniques, including homeostatic model assessment, quantitative insulin sensitivity check index and oral glucose tolerance test-related measures comprising area under the curve for glucose and insulin (Muniyappa et al., 2008).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
- Not checked — no full text of the sourcecites Muniyappa et al., 2008 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“These are based on fasting or post glucose-load blood glucose and insulin levels, yet lack accuracy and reliability and are inadequate for clinical purposes and mechanistic research where IR is a primary study outcome (Muniyappa et al., 2008).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
- Not checked — no full text of the sourcecites Muniyappa et al., 2008 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Low SHBG levels are also increased by insulin-sensitising medication (Ehrmann et al., 1997;Moghetti et al., 2000;Moran et al., 2013);”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Inconsistent reporting of results made it necessary to express variables as factors by dividing the given variable in the PCOS group by that in the respective control group.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The euglycaemic-hyperinsulinaemic clamp is considered the reference standard to directly measure IS in research settings and can be used to define a specific cut-off level for IR (Muniyappa et al., 2008).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Introduction
What the sources say
- Not checked — no full text of the sourcecites Muniyappa et al., 2008 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The inability to acquire missing data from all eligible studies is not unexpected and deemed part of the meta-analysis process (Kelley et al., 2004).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Not checked — no full text of the sourcecites Kelley et al., 2004 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Other key factors may also influence IR in PCOS, including low-grade inflammation (Shorakae et al., 2015) and sympathetic nervous system dysfunction (Diamanti-Kandarakis and Dunaif, 2012;Shorakae et al., 2015) and further research is needed to clarify key mechanisms underpinning IR in PCOS.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Small sample sizes and missing data limited evidence synthesis and meta-analysis.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Also endpoints varied (including units and scales).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This is consistent with mechanistic studies demonstrating that SHBG production is suppressed by IR and hyperinsulinaemia (Le et al., 2012) and that SHBG concentrations increase with insulin sensitiser treatment (Moghetti et al., 2000).”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
What the sources say
- Not checked — no full text of the sourcecites Moghetti et al., 2000 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, not all identified studies were included because of difficulties sourcing the required data from original authors.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The body of evidence was heterogeneous such that diagnostic criteria were not uniformly applied with many studies only including women with NIH-diagnosed PCOS, and few reporting reproductive phenotypes.”
§ Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
The relationships between BMI and insulin sensitivity and between age and insulin sensitivity are linear in the meta-analytic models.
“Fixed effects in the model were either linear numeric variables for BMI and age or a nominal variable for the diagnostic criteria (NIH or Rotterdam).”
The paper relies on this without support.
The diagnostic criteria groupings (NIH versus Rotterdam) are valid surrogates for PCOS phenotype.
“Moderating effects of diagnostic criteria as a surrogate for phenotype”
The paper relies on this without support.
Low SHBG is associated with adverse cardiovascular risk factors, diabetes and metabolic syndrome, independent of obesity.
“Furthermore, low SHBG is associated with adverse cardiovascular risk factors, diabetes and metabolic syndrome, independent of obesity, all important clinical implications of IR in PCOS, suggesting that SHBG may also be a useful clinical marker of metabolic risk in PCOS.”
The paper relies on this without support.
Little prior PCOS literature has reported by phenotype.
“However, little prior PCOS literature has reported by phenotype, necessitating analysis here by diagnostic criteria as a proxy.”
The paper relies on this without support.
Prior studies suggest that women with an NIH diagnosis of PCOS are more insulin resistant than those diagnosed via Rotterdam criteria.
“Prior studies suggest that women with an NIH diagnosis of PCOS are more IR than those diagnosed via Rotterdam criteria.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A systematic review and meta-analysis of euglycemic-hyperinsulinemic clamp studies found that women with PCOS have a 27% reduction in insulin sensitivity compared to body mass index (BMI) and age-matched controls [155].”
From Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment (2022) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the physiology of insulin function is considered to be a quantitative or continuous variable from an evolutionary perspective, it is likely that all women with PCOS, whether obese or lean, have reduced insulin sensitivity [152,155,166].”
From Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment (2022) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the significance of IR as a pathognomonic component of PCOS is an area of debate [153,154,155].”
From Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment (2022) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The level of central adiposity likely plays a key role in cardiometabolic risk, as insulin resistance has been associated with higher levels of central adiposity in the PCOS population [32,34,35,36].”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hyperinsulinemia and insulin resistance play important roles in the pathophysiology of PCOS for both normal-weight women and women with obesity (2, 3, 73, 77).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Having a higher BMI appears to exacerbate insulin resistance by approximately 15% in individuals with PCOS [32].”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“women with PCOS are more likely to be affected by insulin resistance irrespective of body mass index (BMI) (4).”
In the citing paper
“Previous studies found that PCOS women have a significant reduction in insulin sensitivity compared to BMI and age-matched controls [25,39].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [39]
In the citing paper
“Although the etiology is still unknown, obesity, IR and hyperinsulinemia are cardinal features of PCOS [124].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [124]
In the citing paper
“PCOS, characterized by hyperandrogenism, chronic anovulation and/or sonographic evidence of small cysts in one or both ovaries, is the most common endocrinological disorder among women of reproductive age and the main cause of female infertility [124].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [124]
In the citing paper
“This is independent of weight, but is exacerbated by excess weight gain.7,8”
In the citing paper
“It is widely accepted that increased insulin resistance plays a key role in the pathophysiology of PCOS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Adjusted age effect is called both trivial and small
MinorThe discussion calls the BMI- and diagnosis-adjusted age impact trivial, while Table IV labels the corresponding older-versus-younger PCOS effect small and unclear.
“Increasing age adversely impacted IR, yet the impact was trivial when adjusted for BMI and diagnostic criteria.”
“Older PCOS versus younger PCOS -21, ±23 Large (unclear) -7, ±32 ‡ Small (unclear)”
Conclusion reverses the PCOS and control sample counts
MinorThe conclusion assigns 741 participants to PCOS and 1224 to controls; the search-results account assigns those same counts to controls and PCOS, respectively.
“studies (741 women with PCOS and 1224 controls)”
“28 studies (n = 741 controls and n = 1224 PCOS)”
Adjusted BMI effect has the wrong magnitude label
MinorThe paper sets −31% as the threshold for a very large reduction, but labels the adjusted −30% BMI-subgroup effect "Very large." At the reported value, it falls in the large category.
“BMI=32 kg/m 2 (overweight) -31, ±6 Very large**** -30, ±9 † Very large****”
“for reduced IS, the corresponding magnitude thresholds were -3.7, -11, -20 and -31%, respectively.”
Reported age variation is incompatible with the eligibility range
MinorThe table gives one group of eight participants a mean age of 25 years and an age SD of 20 years. An SD that large is impossible if every participant was between 18 and 40 years old, as the selection criteria require.
“Micic et al. (2007) 8, 8 Rotterdam 25 ± 20 22 ± 8”
“participants were premenopausal; 18-40 years of age;”
Two thresholds are given for a very large improvement
MinorThe inferential-statistics section places the very-large improvement threshold at 46%, but the Figure 3 caption places it at 48%.
“For an improvement in IS, magnitude thresholds were 3.8, 12, 25 and 46%, representing small, moderate, large and very large, respectively”
“For an improvement in insulin sensitivity, magnitude thresholds were 3.8, 12, 25, 48 and 120%, representing small, moderate, large, very large and extra large, respectively”
Citations
Cites
Progressive Statistics for Studies in Sports Medicine and Exercise Science
HOPKINS, W. G., MARSHALL, S. W., BATTERHAM, A. M., & HANIN, J. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31818cb278 · Cited by 9,128
Self-citationGlucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,345
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565
Self-citationSterne, J. A. C. (2001) · BMJ · doi:10.1136/bmj.322.7280.226 · Cited by 1,466
Flagged first, then by citations
Research works printed but not linked: 1
- Yang M . A Review of Random Effects Modelling in SAS (Release 8.2). London: London, Centre for Multilevel Modelling, 2003.
Cited by
Sorted by citations
Items 201–300 of 412
Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes
Alshogran, O. Y. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1376648 · Cited by 9
“Hyperandrogenism or testosterone excess is a feature of polycystic ovary syndrome (PCOS) [95], and multiple reports have investigated whether AKR1C3 functional variations contribute to the pathogenesis of PCOS.”
BackgroundInfluentialPolycystic ovary syndrome and offspring risk of congenital heart defects: a nationwide cohort study
Schmidt, A. B., Lund, M., Wohlfahrt, J., & Melbye, M. (2020) · Human Reproduction · doi:10.1093/humrep/deaa168 · Cited by 10
Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs
Cardozo, L. L. Y., & Romero, D. G. (2021) · The FASEB Journal · doi:10.1096/fj.202002526rr · Cited by 9
Yu, L., Xia, Q., Sun, Z., & Song, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9568417 · Cited by 8
“A previous study revealed that about 30∼70% of PCOS patients were overweight or obese [2].”
Wu, D., Zhang, Y., Wu, C., An, B., Wang, X., Ni, J., & Chen, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1578470 · Cited by 11
Çelik, Ö., Yazıcı, D., Ciudin, A., Macut, D., Micić, D., Yumuk, V., & Yıldız, B. O. (2025) · Obesity Facts · doi:10.1159/000547055 · Cited by 13
“Insulin resistance is a central pathophysiological feature of PCOS, occurring independently of obesity; however, obesity can exacerbate insulin resistance, contribute to adipocyte dysfunction, and amplify androgen excess in patients with PCOS [63–65].”
Negahdari, F. M., Hadjzadeh, M., Gholamnezhad, Z., Noshahr, Z. S., & Keshavarzi, Z. (2021) · Europe PMC (PubMed Central) · doi:10.22038/ajp.2021.55679.2785 · Cited by 8
“Hyperandrogenism is a major feature of PCOS, and it occurs due to the overproduction of androgens in the ovaries and high levels of insulin which stimulate ovarian androgen production and suppress liver’s production of sex hormone-binding globulin (Cassar et al., 2016).”
BackgroundAssociation of lipid profile and obesity in patients with polycystic ovary syndrome
Parveen, S., Khan, S., Khan, M. M., Gupta, B., Ahmad, A., & Alam, R. (2024) · Endocrine Regulations · doi:10.2478/enr-2024-0009 · Cited by 11
McBreairty, L. E., Chilibeck, P. D., Chizen, D. R., Pierson, R. A., Tumback, L., Sherar, L. B., & Zello, G. A. (2017) · BMC Nutrition · doi:10.1186/s40795-017-0142-6 · Cited by 8
Contemporary Management of Polycystic Ovarian Syndrome
ZIMMERMAN, L. D., SETTON, R., PEREIRA, N., & ROSENWAKS, Z. (2019) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000449 · Cited by 8
McIlvenna, L. C., Altıntaş, A., Patten, R. K., McAinch, A. J., Rodgers, R. J., Stepto, N. K., Barrès, R., & Moreno‐Asso, A. (2022) · The Journal of Physiology · doi:10.1113/jp282954 · Cited by 8
“, 2016) and is associated with a number of morbidities including subfertility, insulin resistance (Cassar et al., 2016; Stepto et al., 2013), type 2 diabetes mellitus (T2DM) (Moran et al.”
BackgroundSelf-citationJanež, A., Herman, R., Poredoš, P., Mikhailidis, D. P., Blinc, A., Šabović, M., Studen, K. B., Jezovnik, M. K., Schernthaner, G.-H., Anagnostis, P. G., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611269146230920073301 · Cited by 10
Circulating neuregulin-1 levels in polycystic ovary syndrome
Arpacı, H. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2018.1519530 · Cited by 9
“…is a syndrome associated with insulin resistance (IR), failed glucose homeostasis, obesity, hyperlipidaemia, chronic low-grade inflammation and an increased risk of developing type 2 diabetes mellitus (Moran et al. 2010; Teede et al. 2011; Legro et al. 2013; Cassar et al. 2016; Macut et al. 2017).”
BackgroundEe, C., Smith, C. A., Costello, M., Moran, L., Steiner, G. Z., Stepto, N. K., Cave, A. E., Albrehee, A., & Teede, H. J. (2020) · Pilot and Feasibility Studies · doi:10.1186/s40814-020-00591-4 · Cited by 8
Self-citationSánchez-Ferrer, M. L., Árense-Gonzalo, J. J., Prieto‐Sánchez, M. T., Gómez‐Carrascosa, I., Peñalver, A. I. H., Mendiola, J., & Torres-Cantero, A. M. (2021) · Applied Sciences · doi:10.3390/app11125395 · Cited by 7
“This result is in agreement with the conclusion of a metanalysis about insulin resistance on women with PCOS, which concluded that BMI exacerbates insulin resistance in PCOS and has a disproportionately greater impact in PCOS than in controls [50].”
ResultWang, S., Li, F., Zhang, W., Sui, X., & Hao, C. (2022) · Applied Bionics and Biomechanics · doi:10.1155/2022/8323017 · Cited by 7
RetractedInsulin-like peptide 5 is associated with insulin resistance in women with polycystic ovary syndrome
Chen, Y., Chen, J., Li, Y., Wu, Y., Wu, X., Zhang, H., & Zhang, Z. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108493 · Cited by 7
Leithy, A. A. E., Abozaid, M., Al-Karmalawy, A. A., Allam, R. M., Nourelden, A. Z., Amer, R. M., el Azeem, N. H. A., & Abo-Zeid, F. S. (2024) · Gene · doi:10.1016/j.gene.2024.148524 · Cited by 7
The Polycystic Ovary Syndrome (PCOS)
Louwers, Y. V., & Laven, J. S. E. (2020) · Endocrinology · doi:10.1007/978-3-030-14782-2_3 · Cited by 8
Das polyzystische Ovarsyndrom als genderspezifischer kardiometabolischer Risikofaktor
van Baal, L., & Tan, S. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01529-7 · Cited by 7
Zyoud, S. H. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00497-4 · Cited by 10
“These factors can potentially contribute to various metabolic and reproductive complications, such as obesity, disrupted menstrual cycles, and infertility [118, 119].”
BackgroundKuliczkowska-Płaksej, J., Jończyk, M., Jawiarczyk-Przybyłowska, A., Stachowska, B., Zembska, A., Grzegrzółka, J., & Bolanowski, M. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1952975 · Cited by 7
Natural History of Polycystic Ovary Syndrome and New Advances in the Epidemiology
Piltonen, T., Arffman, R. K., & Joham, A. E. (2021) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1735211 · Cited by 7
Guo, X., Chen, L., He, J., Zhang, X., & Xu, S. (2024) · BMC Women s Health · doi:10.1186/s12905-024-03144-6 · Cited by 7
“Moreover, insulin resistance (IR) stands out as a prominent characteristic of PCOS [32].”
BackgroundPolycystic ovary syndrome and miscarriage: a narrative review
Bui, L. M., Aghajanova, L., Lathi, R. B., & Sokalska, A. (2024) · F&S Reviews · doi:10.1016/j.xfnr.2024.100078 · Cited by 6
Soy Isoflavones and PCOS: Role in Hormonal and Metabolic Mechanisms
Dereń, K., Michońska, I., Dymek, A., Zielińska, M., & Łuszczki, E. (2025) · Applied Sciences · doi:10.3390/app15116198 · Cited by 6
Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets
Shirasath, K. R., Ahmed, N. Z., Kumar, P., Alam, S., Karwasra, R., Goyal, S. N., & Agrawal, Y. O. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156245 · Cited by 7
Yao, B., Yu, X., Zhang, Y., Chen, J., Zhu, X., Zhang, C., & Jijun, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1719631 · Cited by 10
“…metabolic manifestations are highly heterogeneous, typically de fi ned by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, often associated with insulin resistance (5) and metabolic syndrome (6, 7), posing long-term reproductive and metabolic health risks for women (8).”
Šumarac-Dumanović, M., Stamenković-Pejković, D., Jeremić, D., Dumanović, J., Mandić, V., Žarković, M., & Micić, D. (2022) · International Journal of Endocrinology · doi:10.1155/2022/6630498 · Cited by 7
“showed a reduction in insulin sensitivity of 27% and obesity exacerbates the reduction in insulin sensitivity by 15% in women with PCOS [23].”
BackgroundRamessur, V., Hunma, S., Joonas, N., Ramessur, B. N., Schütz, Y., Montani, J., & Dulloo, A. G. (2025) · Obesity Facts · doi:10.1159/000543332 · Cited by 8
“The development of obesity, which often leads to increased circulating levels of insulin and androgen, may lead to increased PCOS prevalence and exacerbate its clinical features [4, 7 – 10].”
Modern aspects of management of patients with polycystic ovary syndrome
Авраменко, Н. В., Кабаченко, О. В., Барковський, Д. Є., & Sierykh, К. (2020) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2020.6.218474 · Cited by 6
Liang, H., Li, N., & Li, R. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.08.328 · Cited by 6
Kokori, E., Olatunji, G. D., Komolafe, R., Ogieuhi, I. J., Ukoaka, B. M., Ajayi, I., & Aderinto, N. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00190-9 · Cited by 5
“Preliminary studies have suggested alterations in serum kisspeptin levels in women with PCOS, sparking interest in its potential as a diagnostic biomarker [13, 14].”
BackgroundTosi, F., Lando, M. G., Rosmini, F., Lucarini, F., Fiorio, V., Zanolin, M. E., Fiers, T., Kaufman, J., & Moghetti, P. (2025) · Human Reproduction · doi:10.1093/humrep/deaf114 · Cited by 7
Androgen actions in metabolic tissues in polycystic ovary syndrome
MacRae, C. L., & Campbell, R. E. (2026) · Endocrinology · doi:10.1210/endocr/bqag001 · Cited by 5
Patel, A., Saraf, A., Rao, V. A., & Rao, K. A. (2023) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_145_23 · Cited by 5
Wang, J., Li, L., Zhou, J., Pan, X., Qi, Q., Sun, H., & Wang, L. (2024) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2024.01003 · Cited by 6
Jian, X., Shi, C., Xu, T., Liu, B., Zhou, L., Jiang, L., & Liu, K. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2024.2440063 · Cited by 5
“It has been reported that IR is associated with the pathogenesis and development of PCOS in approximately 50–60% of patients with PCOS (Cassar et al. 2016).”
Alwardi, A. S., AlKaban, R. A., & Abid, A. G. (2018) · International Journal of Advanced Research in Biological Sciences (IJARBS) · doi:10.22192/ijarbs.2018.05.07.004 · Cited by 5
Scannell, N., Mantzioris, E., Rao, V. S., Pandey, C., Ee, C., Mousa, A., Moran, L., & Villani, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11123349 · Cited by 5
Oncostatin M: friend or foe in PCOS pathogenesis?
Nikanfar, S., Oghbaei, F., Nejabati, H. R., Zarezadeh, R., Latifi, Z., Laleh, S. H., Khodavirdilou, L., Khodavirdilou, R., Amorim, C. A., & Fattahi, A. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0140 · Cited by 5
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS?
Livadas, S., Bothou, C., Kuliczkowska-Płaksej, J., Robeva, R., Vryonidou, A., Macut, J. B., Androulakis, I., Opalic, M., Mouslech, Z., Milewicz, A., et al. (2022) · Endocrine Connections · doi:10.1530/ec-21-0358 · Cited by 7
Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women
Бурка, О. А., & Tutchenko, T. М. (2019) · Reproductive Endocrinology · doi:10.18370/2309-4117.2019.46.39-45 · Cited by 5
Pekcan, M. K., Tokmak, A., Akkaya, H., Pekcan, G., Onur, A., Kısa, Ü., & Çil, A. P. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0867-0886 · Cited by 5
“In another study, it was found that the HOMA-IR, SHBG, and fasting insulin levels were similar between PCOS and control groups, after adjusting for BMI and age [33].”
ResultDietary Patterns and Metabolic and Hormonal Parameters in Women with Suspected PCOS
Kowalczyk, K., Kadłubek, S., Krużel, A., Sikora, D., Daniluk, J., & Madej, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082708 · Cited by 4
“A key feature of PCOS is insulin resistance, which significantly elevates the risk of developing impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes, irrespective of a woman’s age or body mass index (BMI) [11].”
Wang, R., Huang, K., Wang, M., Zou, W., Huang, Y., Jiang, W., Feng, Y., Shen, H., & Lei, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1705284 · Cited by 8
Bai, Y., Liu, Y., Wang, Y., Liu, X., Wang, Y., Liu, H., Yi, H., Xu, C., & Zhang, F. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01631-7 · Cited by 5
Lan, Y., Zhong, C., Li, D., Chen, H., & Dai, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1567787 · Cited by 4
Phytotherapy in Polycystic Ovary Syndrome (PCOS) Management: A Systematic Review
Mohamed, S. S., Allam, A. T., Elalfy, A., El‐Shiekh, R. A., Reda, A. M., & Hafeez, M. S. A. E. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500982 · Cited by 6
“IR and compensatory HI are recognized as key contributors to the pathophysiology of PCOS and play critical roles in the development of hyperandrogenemia and reproductive dysfunction through multiple mechanisms [40].”
Clinical management of androgen excess and defect in women
Rosato, E., Sciarra, F., Minnetti, M., Degjoni, A., & Venneri, M. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2279537 · Cited by 4
“It has been shown that insulin-resistance is frequently associated with PCOS, regardless of the patients’ body mass index (BMI) [48].”
BackgroundWeight Changes Are Linked to Adipose Tissue Genes in Overweight Women with Polycystic Ovary Syndrome
Hellberg, A., Salamon, D., Ujvári, D., Rydén, M., & Hirschberg, A. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111566 · Cited by 4
A nomogram to predict the risk of insulin resistance in Chinese women with polycystic ovary syndrome
Guo, B., Shen, Y., Dai, Z., Yimamu, K., Sun, J., & Pei, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1446827 · Cited by 4
Polycystic ovary syndrome potentiates blood pressure and vascular responses to the cold pressor test
Berbrier, D. E., Coovadia, Y., Malenda, D., & Usselman, C. W. (2024) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00697.2024 · Cited by 4
Ma, C., Yu, L., Chen, S., Wu, X., Yang, Y., Xie, H., Chen, X., Liang, X., Peng, Q., Huang, B., et al. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151266 · Cited by 6
The Polycystic Ovary Syndrome (PCOS)
Louwers, Y. V., & Laven, J. S. E. (2020) · Endocrinology · doi:10.1007/978-3-030-03594-5_3-1 · Cited by 6
Polycystic ovary syndrome in adolescence: Toward a better diagnosis and treatment
Evans, A. T., & Hoeger, K. M. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.04.010 · Cited by 4
Polyzystisches Ovarsyndrom – praktische Umsetzung der internationalen Leitlinie
Segerer, S. E., & Keck, C. (2021) · Der Gynäkologe · doi:10.1007/s00129-020-04732-x · Cited by 4
Adipositas – polyzystisches Ovarialsyndrom – Krebs
Weiss, J., & Küpker, W. (2017) · Gynäkologische Endokrinologie · doi:10.1007/s10304-017-0133-3 · Cited by 5
Chang, A. Y., Asokan, A. K., Lalia, A. Z., Sakrikar, D. S., Lanza, I. R., Petterson, X.-M. T., & Nair, K. S. (2024) · Diabetes · doi:10.2337/db23-0977 · Cited by 6
Tehrani, F. R., Fayaz, M., Firouzi, F., Azizi, F., Tohidi, M., & Behboudi‐Gandevani, S. (2025) · Endocrine Connections · doi:10.1530/ec-25-0266 · Cited by 4
“It is reported that it affects 65 – 95% of women with the syndrome, including the vast majority of overweight and obese women, as well as more than half of women of normal weight (36, 37, 38).”
Berbrier, D. E., Huckins, W., Berkel, E. K. V., Delage, S. I., Hannaian, S. J., Myara, R., Okafor, O. N., Chung, T. H., Tulandi, T., Reinblatt, S. L., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00286.2025 · Cited by 3
Hu, X., Zhu, M., Zhou, Q., Li, Z., Luo, L., Liang, W., Chen, S., Pu, X., & Du, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s574929 · Cited by 4
“58,59 While peripheral tissues such as skeletal muscle, adipose tissue, and the liver display blunted insulin responsiveness, the ovaries and adrenal glands retain insulin sensitivity, enabling hyperinsulinemia to directly stimulate androgen production.”
Athamneh, A. A., Farfoura, M. E., Khaleel, A., & Connie, T. (2025) · Genes · doi:10.3390/genes17010028 · Cited by 3
“Insulin resistance plays a crucial role in driving both hyperandrogenism and related clinical symptoms [6,7].”
Serum uric acid levels in patients with different phenotypes of polycystic ovary syndrome
Akkuş, C., Öner, Ö., Kilic, A. O., et al. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_1903_2025 · Cited by 3
“Androgen excess may partly explain the phenotype-specific differences observed 23-25 .”
Targeting metabolism in the management of PCOS: Metformin and beyond
Oğuz, S. H., Şendur, S. N., Ünlütürk, U., & Yıldız, B. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00006-7 · Cited by 5
Wang, Y., Chen, J., Dong, H., Ma, R., Zou, Y., Wang, W., Zheng, Q., Feng, Y., Tan, Z., Zeng, X.-Q., et al. (2022) · BioMed Research International · doi:10.1155/2022/9778678 · Cited by 2
“Existing studies indicate that IR is independent of obesity, and patients are at particular risk of IR regardless of whether they are overweight or lean [27, 28].”
BackgroundRetractedLee, S., An, H., Rhee, S., & Chun, S. (2023) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5011238 · Cited by 3
“According to a systemic review, insulin sensitivity was lower in women with PCOS than in controls [7].”
BackgroundMishra, S., & Mittal, P. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100741 · Cited by 2
Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome: A Race Against the Clock
Huffman, A. M., & Romero, D. G. (2022) · Endocrinology · doi:10.1210/endocr/bqac167 · Cited by 3
Self-reported history of comorbidities and markers of ovarian reserve among subfertile women
Mínguez‐Alarcón, L., Hammer, K. C., Williams, P. L., Souter, I. C., Ford, J. B., Rexrode, K. M., Hauser, R. B., Chavarro, J. E., & for the Earth Study Team (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02643-5 · Cited by 3
Paediatric Obesity Evaluation for Metabolic Susceptibility (POEMS)
Chan, D. W. K., Chua, C., Loh, C. L. Y., Sultana, R., & Vasanwala, R. F. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003228 · Cited by 3
Optimization of ovarian function and metabolic status in syndrome of polycystic ovaries
Татарчук, Т. Ф., Косей, Н. В., Tutchenko, T. М., & Glamazda, M. (2020) · Reproductive Endocrinology · doi:10.18370/2309-4117.2020.52.18-22 · Cited by 4
To explore the relationship between endometrial hyperemia and polycystic ovary syndrome
Wang, S., Li, F., Zhang, W., Bao, H., & Hao, C. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1154 · Cited by 2
“Obesity is a major risk factor for PCOS and represents its most common comorbidity [9].”
Jianli, S., Guan, Z., Ji, G., Wang, J., Yan, X., Zhang, Y., Ha, C., Ha, C., Hu, R., Chang, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202508240 · Cited by 3
Çelik, Z. M., Kurnaz, D., Özcan, A., Keskin, E., Unlugedik, E., & Aktaç, Ş. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70307 · Cited by 6
“The methodological quality of the studies was evaluated using versions 1 and 2 of the Cochrane risk-of-bias tool, ROBINS, designed for quasi-experimental and randomized controlled trials.”
Khalafi, M., Fatolahi, S., Rahmatpanah, G., Symonds, M. E., Rosenkranz, S. K., Dinizadeh, F., & Batrakoulis, A. (2026) · BMC Women s Health · doi:10.1186/s12905-025-04240-x · Cited by 2
“Women diagnosed with PCOS, however, exhibit insulin resistance, irrespective of their body mass index (BMI), suggesting a heightened risk of metabolic dysregulation, even in the absence of obesity [7].”
Ovarian Dysfunction in Polycystic Ovary Syndrome (PCOS)
Mason, H. D., Dilaver, N., & Rice, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_6 · Cited by 3
The Long-Term Health Consequences of Polycystic Ovary Syndrome
Owens, L. A., & Franks, S. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108989831.018 · Cited by 2
Popa, E., Chiş-Şerban, A.-A., & Coman, A. E. (2023) · Medic ro · doi:10.26416/med.151.1.2023.7837 · Cited by 3
Vitamin D and pathophysiology of polycystic ovary syndrome: A case–control study
Basu, B. R., Chakraborty, S., Samaddar, A., Pal, R., Saha, S. K., & Das, N. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_122_22 · Cited by 2
Effect of Wolly Workout in PCOS and PCOD Patients as Part of Management
Tripathi, P. P. (2023) · SSR Institute of International Journal of Life Sciences · doi:10.21276/ssr-iijls.2023.9.4.7 · Cited by 2
“The overproduction of androgen & insulin is the leading cause of early luteinization in granulosa cells ([7]).”
BackgroundGohary, D. S. E. E., Ismail, M. M., Khayat, A. M. E., & Elbohoty, S. B. (2023) · Journal of Medicine in Scientific Research · doi:10.59299/2537-0928.1025 · Cited by 2
The Impact of Microparticulate Air Pollution in Polycystic Ovary Syndrome: A Narrative Review
Stegehuis, N., Kotsirilos, V., & Parker, J. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5110233 · Cited by 4
The multifarious role of insulin in PCOS: From pathophysiology to therapeutic management
Moghetti, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00002-x · Cited by 2
Татарчук, Т. Ф., Tutchenko, T. М., & Бурка, О. А. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103808 · Cited by 2
INSR gene Exome Sequencing Results in patients with PCOS
Arıkan, Y., & Onat, T. (2023) · Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi · doi:10.34087/cbusbed.1358355 · Cited by 2
New Challenges and Perspectives in Polycystic Ovary Syndrome
Parker, J., & Hitch, V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248867 · Cited by 3
“As a result, women with PCOS have a 27% reduction in insulin sensitivity, independent of obesity [19].”
Vitamin D levels in PCOS women and correlation with metabolic parameters
Neelaveni, K., Himaja, K., Rao, P. S., & Sahay, R. K. (2019) · International Journal of Clinical Obstetrics and Gynaecology · doi:10.33545/gynae.2019.v3.i6b.396 · Cited by 1
“Obesity has been shown to negatively impact the glucose metabolism independently and synergistically with insulin resistance ([24]).”
BackgroundLifestyle in Polycystic Ovary Syndrome
Garad, R. M., Lim, S. S., & Moran, L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108989831.010 · Cited by 1
Marouf, B. H. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s377404 · Cited by 1
“Insulin resistance, with reflex hyperinsulinemia, plays a part in metabolic changes associated with PCOS, and therefore PCOS and insulin resistance are often interrelated.(4,5) In addition, androgen elevation and higher luteinizing hormone (LH) level are the principal biochemical abnormalities in women with PCOS.”
BackgroundDie neue internationale PCOS-Leitlinie – welche Neuerungen bringt das erste Update?
Segerer, S. E., & Sonntag, B. (2024) · Die Gynäkologie · doi:10.1007/s00129-023-05185-8 · Cited by 1
Forslund, M., Melin, J. M., Piltonen, T., et al. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14892 · Cited by 1
Rona, G. (2025) · Northern Clinics of Istanbul · doi:10.14744/nci.2024.34033 · Cited by 1
“…a range of comorbidities that pose substantial public health concerns, including insulin resistance, type 2 diabetes, cardiovascular diseases, dyslipidemia, hypertension, non-alcoholic fatty liver disease, infertility, endometrial cancer, as well as depression, anxiety, and eating disorders [4–10].”
Ohikhuai, E. E., Akueme, N. T., Olaniyi, S., Iyun, O. B., Thomas, R., Kanu, C. J., Wiredu, B., Narendrula, T., & Okobi, O. E. (2025) · Cureus · doi:10.7759/cureus.85281 · Cited by 1
“A meta-analysis of 28 studies also demonstrated higher insulin resistance in individuals with SCH, which is intriguing as insulin resistance is a central pathogenic feature of PCOS [19].”
Common pathogenetic mechanisms of non-alcoholic fatty liver disease and polycystic ovary syndrome
Ilovayskaya, I. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-90-97 · Cited by 1
Zhang, S., Sun, X., Guan, H., Wang, R., Zhang, W., & Xia, H. (2025) · Obesity Reviews · doi:10.1111/obr.70008 · Cited by 3
“It is important to note that nearly all women with PCOS exhibit reduced insulin sensitivity, with studies reporting an average reduction of 27% [33].”
Polycystic ovary syndrome and idiopathic central precocious puberty: two sides of the same coin?
Cela, E., Tarantino, C., Vincenzi, L., Tenuta, M., Pozza, C., Minnetti, M., & Sbardella, E. (2025) · Endocrine · doi:10.1007/s12020-025-04461-y · Cited by 1
“In PCOS, insulin resistance is frequently observed, clini - cally measurable in 50 to 70% of females with the condition, irrespective of overweight or obesity status [ 168].”
Insulin Resistance in the Pathophysiology of Polycystic Ovary Syndrome
Chada, S. R., & Sahay, R. K. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810931125010014 · Cited by 1
Lu, F., Yu, H., Shi, B., Feng, J., Liu, Y., Guan, M., Yu, J., Gao, Z., Gao, J., Ma, H., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1716287 · Cited by 4
Yan, Q., Cai, M., Wang, N., et al. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70092 · Cited by 1
Metadata
- Authors
- Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K.
- Affiliations
- Monash Health (AU)
- Deakin University (AU)
- Corresponding author
- Stepto, Nigel K.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-07
- Volume
- 31
- Issue
- 11
- Pages
- 2619-2631
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2528179062
- Semantic Scholar
- 7bd1e54cb161a47c607c26284f2c1061e768c318
- Cited by
- 415
- References
- 79
- Citations by year
- 2026: 54 · 2025: 51 · 2024: 59 · 2023: 54 · 2022: 46 · 2021: 42 · 2020: 36 · 2019: 30 · 2018: 22 · 2017: 20 · 2016: 1
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Victoria University Research Repository (Victoria University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Australian Government
- Monash University
- Medical Research Council
- National Health and Medical Research Council (606553)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, insulin resistance, insulin sensitivity, body mass index, hyperinsulinemic-euglycemic clamp, PCOS diagnostic criteria, NIH criteria, Rotterdam criteria, sex hormone-binding globulin, hyperandrogenism, hyperinsulinemia, hypertriglyceridemia, hyperlipidemia, hyperuricemia, hyperoestrogenism
- MeSH terms
- Female, Humans, Insulin Resistance, Polycystic Ovary Syndrome, Glucose Clamp Technique, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
